Exact Sciences (EXAS) AI Stock Analysis

• Market Cap: $19.25B
• Dividend Yield: N/A
• Average Volume (3M): 6.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: 14.47%
• EPS Growth: -353.69%
• Country: US
• Employees: 6,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.10
• Shares Outstanding: 189,765,820
• 10 Day Avg. Volume: 15,035,047
• 30 Day Avg. Volume: 6,983,463
• PEG Ratio: -0.03
• Price to Book (P/B): 4.31
• Price to Sales (P/S): 3.75
• P/FCF Ratio: 138.84
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 3.86
• Enterprise Value/Gross Profit: 5.73
• Enterprise Value/Ebitda: -15.61
• 1Y Price Target: $96.06
• Price Target Upside: -5.16% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 21
• EPS Forecast (FY): -0.7
• Revenue Forecast (FY): $3.23B

• Rating: 62 Neutral
• Price Target: $71.00 ▼(-29.90% Downside)

Exact Sciences' stock score is primarily driven by strong technical indicators and positive earnings call sentiment, reflecting robust revenue growth and strategic product launches. However, the company's financial performance and valuation are weighed down by ongoing profitability challenges and a negative P/E ratio, which temper the overall score.

Positive Factors

Revenue Growth

The 20% YoY revenue growth indicates strong demand for Exact Sciences' products, particularly Cologuard, supporting long-term market expansion and financial health.

Product Innovation

The launch of Cancerguard enhances Exact Sciences' product portfolio, positioning it as a leader in cancer diagnostics and driving future revenue streams.

Strategic Acquisition

The acquisition by Abbott provides Exact Sciences with increased resources and market reach, potentially accelerating growth and innovation in cancer diagnostics.

Negative Factors

Profitability Challenges

Ongoing profitability challenges could hinder Exact Sciences' ability to reinvest in growth and innovation, impacting long-term financial stability.

Gross Margin Decline

A decline in gross margins indicates potential cost pressures and efficiency issues, which could affect future profitability and competitiveness.

High R&D Expenses

While R&D is crucial for innovation, high expenses without immediate returns can strain financial resources and delay profitability improvements.

Exact Sciences Business Overview & Revenue Model

Company Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

How the Company Makes Money

Exact Sciences generates revenue primarily through the sale of its diagnostic tests, with Cologuard being the most significant contributor to its earnings. The company operates on a direct-to-consumer model as well as through partnerships with healthcare providers and laboratories. It bills insurance companies and Medicare for the tests performed, which is a key revenue stream. Additionally, Exact Sciences has established strategic partnerships with other healthcare organizations and life sciences companies to expand its reach and enhance its testing portfolio, further driving its revenue growth. The company also invests in research and development to innovate and introduce new products, which can lead to additional revenue opportunities.

Exact Sciences Financial Statement Overview

Summary

Exact Sciences shows moderate revenue growth and improving cash flow, which are positive indicators. However, challenges with profitability and return on equity persist, and the company needs to enhance operational efficiency and profitability to improve overall financial health.

Income Statement

Exact Sciences shows a moderate revenue growth rate of 4.83% TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The gross profit margin remains relatively strong at 68.19%, but the consistent net losses highlight ongoing challenges in achieving operational efficiency.

Balance Sheet

The company's debt-to-equity ratio of 1.02 TTM suggests a balanced approach to leveraging, but the negative return on equity indicates that the company is not generating sufficient returns on shareholders' investments. The equity ratio is not provided, but the overall leverage appears manageable, albeit with room for improvement in profitability.

Cash Flow

Exact Sciences has shown a significant improvement in free cash flow growth at 45.67% TTM, which is a positive sign. The operating cash flow to net income ratio of 0.59 indicates some efficiency in converting income to cash, though the free cash flow to net income ratio of 0.56 suggests that cash generation relative to net income could be better.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.08B	2.76B	2.50B	2.08B	1.77B	1.49B
Gross Profit	2.08B	1.92B	1.76B	1.42B	1.31B	1.14B
EBITDA	-761.42M	-789.33M	29.28M	-421.11M	-649.28M	-653.88M
Net Income	-986.58M	-1.03B	-204.15M	-623.51M	-595.63M	-823.61M
Balance Sheet
Total Assets	5.90B	5.93B	6.47B	6.23B	6.68B	4.93B
Cash, Cash Equivalents and Short-Term Investments	1.00B	1.04B	777.64M	632.06M	1.03B	1.84B
Total Debt	2.54B	2.75B	2.55B	2.45B	2.38B	2.33B
Total Liabilities	3.40B	3.53B	3.33B	3.18B	3.30B	2.69B
Stockholders Equity	2.50B	2.40B	3.15B	3.04B	3.39B	2.24B
Cash Flow
Free Cash Flow	247.08M	74.55M	31.93M	-438.02M	-238.00M	72.13M
Operating Cash Flow	386.81M	210.54M	156.12M	-223.56M	-102.24M	136.48M
Investing Cash Flow	62.13M	-442.15M	49.68M	74.07M	-1.08B	-702.04M
Financing Cash Flow	-251.72M	231.87M	159.77M	76.48M	8.47M	1.88B

Exact Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 101.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXAS, the sentiment is Positive. The current price of 101.29 is above the 20-day moving average (MA) of 78.55, above the 50-day MA of 66.70, and above the 200-day MA of 53.78, indicating a bullish trend. The MACD of 10.48 indicates Negative momentum. The RSI at 90.74 is Negative, neither overbought nor oversold. The STOCH value of 98.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EXAS.

Exact Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$883.61M	14.41	24.11%	―	14.46%	―
QGEN	77 Outperform	$10.35B	25.76	11.29%	3.14%	5.32%	336.29%
EXAS	62 Neutral	$19.25B	―	-34.54%	―	14.47%	-353.69%
FLGT	60 Neutral	$932.01M	―	-3.80%	―	13.60%	74.64%
GH	58 Neutral	$14.03B	―	―	―	30.38%	24.17%
NEO	55 Neutral	$1.57B	―	-12.99%	―	10.10%	-44.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Exact Sciences Corporate Events

Exact Sciences Reports Record Q3 Revenue and Raises Guidance

Exact Sciences Corp., a prominent player in the cancer screening and diagnostics sector, continues to innovate with products like Cologuard® and Cancerguard, aiming to enhance early cancer detection and patient outcomes.

Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer

Study Overview: The EXActDNA-003 / NSABP B-64 study, officially titled ‘Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease,’ aims to explore the use of a circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD) in patients with high-risk early breast cancer. This study is significant as it seeks to improve recurrence prediction, potentially enhancing patient outcomes.

Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection

Exact Sciences Corp is currently recruiting participants for its study titled ‘Falcon – The Exact Sciences Multicancer Early Detection (MCED) Real World Evidence (RWE) Registry.’ The primary objective of this study is to gather real-world evidence on the performance of the Exact Sciences MCED test, which is significant for advancing early cancer detection methods.

Exact Sciences Corp’s Strong Earnings Call Highlights

Exact Sciences Corp’s recent earnings call showcased a robust performance, marked by impressive revenue and EBITDA growth. The company highlighted successful expansions and new coverage agreements, which are set to bolster future prospects. However, challenges such as underperformance in blood-based test results and restructuring costs were also noted, impacting the financial landscape.

Exact Sciences Corp. Reports Strong Q2 2025 Results

Exact Sciences Corp., a prominent player in the cancer screening and diagnostics sector, continues to innovate and expand its offerings, providing vital tools for early cancer detection and management.

Exact Sciences Announces Collaboration with Freenome Holdings

On August 6, 2025, Exact Sciences announced a collaboration with Freenome Holdings to develop blood-based colorectal cancer screening products. The company reported record second-quarter revenue of $811 million, a 16% increase from the previous year, and raised its full-year revenue and adjusted EBITDA guidance. Key achievements included gaining Medicare coverage for its Oncodetect test and launching a multi-year productivity plan targeting $150 million in savings by 2026.

The most recent analyst rating on (EXAS) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.